Dr. Christopher Jones is a board-certified radiation oncologist who specializes in
the use of ionizing radiation to treat cancer, focusing on tumors of the head and
neck, prostate, and brain. He investigates optimal use of radiation therapy (radiotherapy)
techniques including intensity modulated radiation therapy (IMRT), high-dose brachytherapy,
and image-guided radiation therapy. Dr. Jones is a Principal Investigator for Radiation
Therapy Oncology Group (RTOG) National Cancer Institute-sponsored oncology group clinical
trials. He has authored numerous publications and abstracts on radiotherapy and imaging
techniques to assess cancer progression, predict tumor recurrence after surgery and
radiotherapy, and visualize response to treatment. Dr. Jones lectures nationally and
internationally on the role of radiation therapy in the management of head and neck
cancers.
Sutter Health Research Enterprise
2800 L Street, #10
Sacramento, CA, 95816
(916) 454-6600
simr@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant (ECOG-ACRIN EA3191)
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation
or Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra
Investigator: Christopher Jones MD
Status: Active, Recruiting
Adjuvant (NRG BN003)
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II
Meningioma That Has Been Completely Removed by Surgery
Investigator: Christopher Jones MD
Status: Active, Recruiting
Adjuvant (RTOG 3506 STEEL)
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen
Deprivation Therapy (with Enzalutamide)
Investigators: Christopher Jones MD, Sivakumar Reddy M.D., Seth A Rosenthal Radiation Oncologist, David S Yee M.D., MPH
Status: Active, Recruiting
Adjuvant NRG HN001
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer
Based on EBV DNA
Investigator: Christopher Jones MD
Status: Active, Recruiting
COMPPARE
A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate
Cancer (COMPPARE)
Investigator: Christopher Jones MD
Status: Active, Recruiting
First Line or Neoadjuvant (NRG-HN005)
De-intensified Radiation Therapy With Cisplatin or Nivolumab in Treating Patients
With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG GU005)
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating
Patients With Stage IIA-B Prostate Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced (NRG HN004) Temporarily on Hold
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally
Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Investigator: Christopher Jones MD
Status: Active, Not Recruiting
Locally Advanced (RTOG 1216)
Randomized Phase II/III Trial of Adjuvant Radiation Therapy (RT) with Cisplatin, Docetaxel
Cetuximab, or Cisplatin Atezolizumab in Pathologic High Risk Squamous
Investigator: Christopher Jones MD
Status: Active, Recruiting
Locally Advanced or Metastatic (NRG CC003)
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients
With Limited Stage or Extensive Stage Small Cell Lung Cancer
Investigator: Christopher Jones MD
Status: Active, Recruiting
Lung Cancer (PACIFIC-4 / RTOG-3515)
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International
Study of Durvalumab following stereotactic body radiation therapy (SBRT)
Investigators: Deepti Behl MD, Carlin R Hauck Radiation Oncologist, Christopher Jones MD, Charlotte D Kubicky Radiation Oncologist, Hubert Y Pan Radiation Oncologist, Anthony T Pu Radiation Oncologist, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Metastatic (NRG-BN009)
Testing the Addition of HA-WBRT to SRS in People With Cancer That Has Spread to the
Brain and Come Back in Other Areas of the Brain After Earlier SRS
Investigator: Christopher Jones MD
Status: Active, Recruiting